New and Coming Soon: Psychedelic Healing Center, Cocoon, Juilliard Station

The space at 408 Columbus Avenue (corner of 79th Street) which was previously home to a Halstead Property office will soon be taken over by Cocoon, a membership-based “social and learning club for families.” Expected to open in November, the 14,000 square foot, three-floor space will offer classes and programs for babies, toddlers, and kids up to eight, according to its website. Memberships are priced at $600 per month. This will be Cocoon’s second location; their original spot is in Tribeca. Class categories include art, science, sports, music and cooking, according to Cocoon’s website. They also offer a day camp and private parties.

Verizon Wireless has leased a long-vacant space at 2875 Broadway (corner of 112th Street), according to @TradedNY, which states that the 1,350 square foot storefront has been leased at $400 per foot (per year). That’s an annual rent of $540,000, or $45,000 per month.

Advertisement


Juilliard has opened a pop-up “street-side studio” on 66th and Broadway in the space that was previously home to WNET studio. Juilliard Station will host “drop in Open Houses, student recitals and rehearsals, early evening ‘Rush Hour’ concerts, pre-concert lectures, chamber music playthroughs, guest speakers and masterclasses, Juilliard store sales, Extension and Prep Division activities, as well as sign-ups for classes in the Extension Division and other special events,” according to a recent press release. To see the upcoming schedule, click here.

Mount Sinai Health System has expanded its psychedelic psychotherapy research center with a new location at 600 West 112th Street (corner of Broadway). The Parsons Research Center for Psychedelic Healing comes with six treatment rooms and a group therapy room, and according to a press release, a lot of natural light and a comforting design to help patients heal. The new center was “designed to support the Center’s capacity to facilitate a growing number of rigorous clinical trials that focus on well-known compounds like MDMA, psilocybin, ketamine, and potentially others in the future.”


.





Leave a Reply

Advertisement